Marksans Pharma- Can it be the next Pharma Biggie?

Received marketing auth

• Q1FY25 to be EBITDA level break even for Teva
• The product mix from Teva can expect better margin profiles.
• very bullish on the U.S. market. It is our growth driver for the next 2 years. In 1-2 years, aiming to double revenue here. 100 million to 200 million
• we are investing into the next phase for Teva , which will take us to 5-plus billion units. That 5-plus billion units will probably come after September – in the second half of the year – financial year. But hopefully, by the end of this year, we will have a decent run rate of revenue coming out from the Teva
  plant